GLUE vs ODTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GLUE · Monte Rosa Therapeutics$10.57 ▲ 3.12%
ODTX · Odyssey Therapeutics$19.23 ▲ 1.85%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GLUE -45.5%
- ODTX +17.1%
Head to head
| Metric | GLUE | ODTX |
|---|---|---|
| Price | $10.57 | $19.23 |
| Change today | ▲ 3.12% | ▲ 1.85% |
| Market cap | $903.21M | $924.35M |
| Return, 3 months | -33.2% | -13.3% |
| Return, year to date | -32.6% | – |
| Return, 1 year | -14.1% | – |
| P/E (TTM) | – | – |
| P/B | 1.8 | 2.5 |
| P/E percentile vs own 5y | 12th | 49th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -61.3% | -100.0% |
| Net profit growth (YoY) | -253.0% | -28.0% |
| Gross margin | – | – |
| Operating margin | -633.0% | -161,887.9% |
| Net margin | -560.9% | -161,643.4% |
| Return on equity | -42.7% | -38.0% |
| Analyst target vs. price | +157.0% | +83.7% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 45 | 47 |
| 30-day volatility | 58.0% | 78.6% |
| Max drawdown, 1 year | -61.5% | -42.3% |
| Trend read | Strong downtrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ODTX is the largest of the group by market value.
- GLUE is growing revenue fastest.
- GLUE keeps the most profit per dollar of sales.
- GLUE has been the calmest stock over the last 30 days.